No takes yet. Share an insight, caveat, or question.
Novel strategy shows enhanced PARP inhibitor sensitivity in pancreatic cancer by inducing homologous recombination deficiency.
Zarei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: